BioCryst Pharmaceuticals Future Growth
Future criteria checks 4/6
BioCryst Pharmaceuticals is forecast to grow earnings and revenue by 72.8% and 15.3% per annum respectively while EPS is expected to grow by 72.6% per annum.
Key information
72.8%
Earnings growth rate
72.6%
EPS growth rate
Biotechs earnings growth | 27.8% |
Revenue growth rate | 15.3% |
Future return on equity | n/a |
Analyst coverage | Good |
Last updated | 19 Nov 2024 |
Recent future growth updates
Recent updates
BioCryst Pharmaceuticals: Seasoned Blockbuster Makes It A Buy
Dec 09BioCryst's Orladeyo Outperforms, But Competition Remains A Threat (Rating Upgrade)
Sep 29Analysts Are Upgrading BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) After Its Latest Results
Aug 08Betting On BioCryst Pharmaceuticals: Orladeyo's Success Fuels Future Prospects
Jul 21BioCryst: Estimate-Beating Q1 But Risks Are Considerable
May 07Insufficient Growth At BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Hampers Share Price
Apr 29BioCryst's Revenue Gains Offset By Rising Expenses: A Closer Look
Feb 27BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Price Is Right But Growth Is Lacking After Shares Rocket 34%
Jan 09BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Shares Lagging The Industry But So Is The Business
Jun 08BioCryst Pharmaceuticals: Working To Increase Market Presence Of Orladeyo
Oct 11BioCryst Pharmaceuticals promotes Sheridan to development chief
Sep 14BioCryst wins FDA’s Orphan Drug status for bone disorder therapy
Aug 31BioCryst to supply 10K doses of influenza drug Rapivab to US for ~$7M
Aug 25BioCryst Orladeyo gets approval in Saudi Arabia to prevent hereditary angioedema attacks
Aug 18BioCryst Pharmaceuticals Q2 2022 Earnings Preview
Aug 03BioCryst Pharmaceuticals: Waiting For Clarity
Jul 25BioCryst: A Prudent Diversification
Jun 24Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 625 | 74 | 170 | N/A | 8 |
12/31/2025 | 534 | -14 | 93 | 46 | 10 |
12/31/2024 | 446 | -78 | 5 | -52 | 9 |
9/30/2024 | 413 | -124 | -57 | -56 | N/A |
6/30/2024 | 382 | -146 | -86 | -84 | N/A |
3/31/2024 | 355 | -209 | -104 | -101 | N/A |
12/31/2023 | 331 | -227 | -97 | -95 | N/A |
9/30/2023 | 318 | -236 | -112 | -110 | N/A |
6/30/2023 | 307 | -243 | -124 | -123 | N/A |
3/31/2023 | 290 | -226 | -133 | -132 | N/A |
12/31/2022 | 271 | -247 | -163 | -162 | N/A |
9/30/2022 | 238 | -193 | -172 | -170 | N/A |
6/30/2022 | 204 | -210 | -163 | -161 | N/A |
3/31/2022 | 188 | -194 | -162 | -159 | N/A |
12/31/2021 | 157 | -184 | -145 | -142 | N/A |
9/30/2021 | 114 | -227 | -154 | -152 | N/A |
6/30/2021 | 79 | -214 | -168 | -167 | N/A |
3/31/2021 | 32 | -209 | -173 | -173 | N/A |
12/31/2020 | 18 | -183 | -136 | -135 | N/A |
9/30/2020 | 54 | -125 | -103 | -103 | N/A |
6/30/2020 | 49 | -116 | -93 | -92 | N/A |
3/31/2020 | 48 | -115 | -86 | -86 | N/A |
12/31/2019 | 49 | -109 | -90 | -90 | N/A |
9/30/2019 | 12 | -134 | -103 | -103 | N/A |
6/30/2019 | 12 | -126 | -111 | -111 | N/A |
3/31/2019 | 23 | -107 | -100 | -100 | N/A |
12/31/2018 | 21 | -101 | -93 | -93 | N/A |
9/30/2018 | 22 | -93 | -79 | -79 | N/A |
6/30/2018 | 29 | -79 | N/A | -56 | N/A |
3/31/2018 | 20 | -77 | N/A | -52 | N/A |
12/31/2017 | 25 | -66 | N/A | -41 | N/A |
9/30/2017 | 30 | -51 | N/A | -36 | N/A |
6/30/2017 | 29 | -47 | N/A | -42 | N/A |
3/31/2017 | 31 | -47 | N/A | -43 | N/A |
12/31/2016 | 26 | -55 | N/A | -53 | N/A |
9/30/2016 | 22 | -69 | N/A | -62 | N/A |
6/30/2016 | 25 | -72 | N/A | -58 | N/A |
3/31/2016 | 46 | -51 | N/A | -28 | N/A |
12/31/2015 | 48 | -43 | N/A | -13 | N/A |
9/30/2015 | 49 | -37 | N/A | -12 | N/A |
6/30/2015 | 41 | -31 | N/A | -8 | N/A |
3/31/2015 | 17 | -50 | N/A | -33 | N/A |
12/31/2014 | 14 | -45 | N/A | -39 | N/A |
9/30/2014 | 19 | -39 | N/A | -29 | N/A |
6/30/2014 | 18 | -38 | N/A | -28 | N/A |
3/31/2014 | 17 | -36 | N/A | -24 | N/A |
12/31/2013 | 17 | -30 | N/A | -27 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BCRX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).
Earnings vs Market: BCRX is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: BCRX is expected to become profitable in the next 3 years.
Revenue vs Market: BCRX's revenue (15.3% per year) is forecast to grow faster than the US market (9.1% per year).
High Growth Revenue: BCRX's revenue (15.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if BCRX's Return on Equity is forecast to be high in 3 years time